Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Squamous Cell Carcinoma of Head and Neck 44Lung Neoplasms 36Urinary Bladder Neoplasms 22Oropharyngeal Neoplasms 22Head and Neck Neoplasms 19Nasopharyngeal Carcinoma 18Carcinoma 16Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14Esophageal Squamous Cell Carcinoma 14Uterine Cervical Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Cholangiocarcinoma 13Ovarian Neoplasms 12Colorectal Neoplasms 12Pancreatic Neoplasms 11Carcinoma, Squamous Cell 11Laryngeal Neoplasms 10Stomach Neoplasms 9Mouth Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Mesothelioma, Malignant 6

Interventions

Nivolumab 5Cyclophosphamide 5pembrolizumab 4Ipilimumab 4fludarabine phosphate 3fludarabine 3Specimen Handling 3Radiosurgery 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Blood Specimen Collection 2trametinib 1tebentafusp 1ruxolitinib 1omipalisib 1olaparib 1lifileucel 1binimetinib 1belinostat 1avelumab 1Vorinostat 1Valproic Acid 1Tape Recording 1Sunitinib 1Spinal Puncture 1Practice Guidelines as Topic 1Pemetrexed 1Methods 1LY2940680 1Iodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Cisplatin × 90 days × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡